泊沙康唑预防和治疗侵袭性真菌感染的进展  

A review of posaconazole application in the treatment of invasive fungal disease

作　　者：李念夷[1] 王小钦[1] 

机构地区：[1]复旦大学附属华山医院血液科,上海200040

出　　处：《中国新药杂志》2014年第23期2739-2747,2757,共10页Chinese Journal of New Drugs

摘　　要：泊沙康唑是口服的第2代三唑类广谱抗真菌药物,其抗真菌谱广,抗菌效力强,尤其对比较罕见而且威胁生命的侵袭性真菌感染有效,主要用于预防和治疗严重免疫功能缺陷患者的侵袭性真菌感染。泊沙康唑不仅在药效上强于第1代三唑类抗真菌药,如氟康唑和伊曲康唑,且根据临床经济学分析的结果,其具有更好的成本-效果。Posaconazole is an oral second-generation triazole with extended-spectrum, and its approved indications include prophylaxis of invasive fungal diseases in immunocompromised patients, especially to treat the in- vasive infections by relatively rare but life-threatening fungus like Zygomycosis, Fusarium disease, coccidioidomycosis and so on. Posaconazole is not only more clinically effective than first-generation triazole antifungal drugs, for example, fluconazole and itraconazole, but also more cost-effective according to clinical economic analysis. In this paper, the strategy of treatment with posaconazole to invasive fungal infection was reviewed.

关 键 词：泊沙康唑 深部真菌感染 临床疗效 临床经济学 成本-效果 成本-效用 

分 类 号：R978.5[医药卫生—药品]